Cargando…
Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study
Some statins (simvastatin, lovastatin, and atorvastatin) are metabolized by cytochrome P450s 3A4 (CYP3A4). Inhibitors of CYP3A4 including some calcium channel blockers (CCBs) might increase statin blood concentration, owing to drug–drug interactions. Risk of adverse events such as acute kidney injur...
Autores principales: | Wang, Yi-Chun, Hsieh, Tsung-Cheng, Chou, Chu-Lin, Wu, Jung-Lun, Fang, Te-Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718284/ https://www.ncbi.nlm.nih.gov/pubmed/26765458 http://dx.doi.org/10.1097/MD.0000000000002487 |
Ejemplares similares
-
Topiramate-related adverse events: Pattern and signals in the Korea Adverse Event Reporting System, 2010-2017
por: Choi, Junyeong, et al.
Publicado: (2020) -
Comparing Characteristics of Adverse Drug Events Between Older and Younger Adults Presenting to a Taiwan Emergency Department
por: Chen, Yen-Chia, et al.
Publicado: (2015) -
Statin in the treatment of patients with myocardial infarction: A meta-analysis
por: Han, Xue, et al.
Publicado: (2018) -
Sex disparities in the effect of statins on lipid parameters: The PharmLines Initiative
por: Hunt, Nicholas B., et al.
Publicado: (2022) -
Suspected adverse events following immunization against SARS-CoV2 in a university hospital in 2021: Observational study
por: Rodríguez, Dolores, et al.
Publicado: (2022)